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Abstract: Cellular reprogramming of somatic cells to human pluripotent stem cells (iPSC) 
represents an efficient tool for in vitro modeling of human brain diseases and provides an 
innovative opportunity in the identification of new therapeutic drugs. Patient-specific iPSC 
can be differentiated into disease-relevant cell types, including neurons, carrying the 
genetic background of the donor and enabling de novo generation of human models of 
genetically complex disorders. Parkinson’s disease (PD) is the second most common  
age-related progressive neurodegenerative disease, which is mainly characterized by 
nigrostriatal dopaminergic (DA) neuron degeneration and synaptic dysfunction. Recently, 
the generation of disease-specific iPSC from patients suffering from PD has unveiled a 
recapitulation of disease-related cell phenotypes, such as abnormal α-synuclein accumulation 
and alterations in autophagy machinery. The use of patient-specific iPSC has a remarkable 
potential to uncover novel insights of the disease pathogenesis, which in turn will open 
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new avenues for clinical intervention. This review explores the current Parkinson’s disease 
iPSC-based models highlighting their role in the discovery of new drugs, as well as 
discussing the most challenging limitations iPSC-models face today. 
Keywords: induced pluripotent stem cells; Parkinson’s disease; Leucine-rich repeat kinase 
2 (LRRK2); dopaminergic neurons 
 
1. Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disease in the world after 
Alzheimer’s disease (AD), affecting 2% of the population over the age of 60. The mean duration of the 
disease from the time of diagnosis to death is approximately 15 years, with a mortality ratio of 2 to 1 in the 
affected subjects [1]. 
PD is characterized by debilitating motor deficits, such as tremor, limb rigidity and slowness of 
movements (bradykinesia) although non-motor features, such as hyposmia, cognitive decline, depression, 
and disturbed sleep are also present in later stages of the disease [1–3]. Neuropathologically, these motor 
deficits are caused by the progressive preferential loss of striatal-projecting neurons of the substantia nigra 
pars compacta; more specifically a subtype of dopaminergic neurons (DAn) patterned for the ventral 
midbrain (vmDAn). Neuronal loss is typically accompanied by the presence of intra-cytoplasmic  
ubiquitin-positive inclusions in surviving neurons. These structures are known as Lewy bodies and Lewy 
neurites and they are mainly composed of the neuronal protein α-synuclein (α-syn). These protein 
inclusions are not only found throughout the brain but also outside of the CNS. Moreover, microglial 
activation and an increase in astroglia and lymphocyte infiltration also occur in PD [4]. 
Approximately 90%–95% of all PD cases are sporadic with no family history. Although disease onset 
and age are highly correlated, PD occurs when complex mechanisms such as mitochondrial activity, 
autophagy or degradation via proteasome are dysregulated by environmental influence or PD-specific 
mutation susceptibility [5]. 
Studies of rare large families showing classical Mendelian inherited PD have allowed for the 
identification of 11 genes out of 16 identified disease loci. They include dominant mutations in  
Leucine-rich repeat kinase 2 (LRRK2), recessive mutations in Parkin (coded by PARK2) and  
PTEN-induced putative kinase (PINK1) [6], as well as both rare dominant mutations and multiplications in 
the gene encoding α-synuclein (SNCA).  
Current treatment for PD is limited to targeting only the symptoms of the disease and does not cure or 
delay disease progression. Therefore, the identification of new and more effective drugs to slow down, stop 
and even reverse PD is critical. This limited symptomatic treatment is due to the lack of clear 
understanding of the underlying mechanisms affected during PD. Using patient-specific iPSC-based 
models to recapitulate the disease from start to finish delivers a more detailed picture of the mechanisms 
involved in the progression of Parkinson’s disease and will aid in the discovery of disease-targeted 
therapies in the future.  
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2. Models of Parkinson’s Disease 
Despite advances in the identification of genes and proteins involved in PD, there are still gaps in our 
understanding of the underlying mechanisms involved [7,8]. The lack of PD models fully representing the 
complex mechanisms involved in disease progression, as well as the near impossible task of extracting live 
neurons from patients has proven the investigation of PD difficult [8]. In general, genetic mouse models do 
not represent the pathophysiological neurodegeneration and protein aggregation pattern observed in PD 
patients [9,10], and are thus limited [11,12]. On the other hand, PD animal models of administration of 
neurotoxins systemically or locally have successfully replicated DAn neurodegeneration, however they fail 
to recapitulate the degeneration in a slow and progressive manner, nor the formation of Lewy body-like 
inclusions which occur in PD human pathology [13]. 
Although the cellular models of PD, mostly based on human neuronal tumor cell lines, have provided 
helpful insights into alterations in specific subcellular components (such as proteasome, lysosome and 
mitochondrion), the relevance of these findings for PD pathogenesis is not always immediate. These 
models do not, however, investigate the defective mechanisms within the predominantly affected cell in 
PD, the DAn [14]. In addition, all studies involving human tissue have been performed with post-mortem 
samples, which can only allow for a limited analysis.  
The recent discovery of cellular reprogramming to generate induced pluripotent stem cells (iPSC) from 
patient somatic cells offers a remarkable opportunity to generate disease-specific iPSC [15], and to 
reproduce at a cellular and molecular level the mechanisms involved in disease progression. The use of 
iPSC offers not only the possibility of addressing important questions such as the functional relevance of 
the molecular findings, the contribution of individual genetic variations, patient-specific response to 
specific interventions, but also helps to recapitulate the prolonged time-course of the disease (Figure 1). 
3. Generation of PD-Specific iPSCs 
In recent years, neurodegenerative disease research has quickly advanced with the help of stem cell 
technology reprogramming somatic cells, such as fibroblasts, into induced pluripotent stem cells  
(iPSC) [15]. Human iPSC share many characteristics with human embryonic stem cells (hESC), including 
similarities in their morphologies, gene expression profiles, self-renewal ability, and capacity to 
differentiate into cell types of the three embryonic germ layers in vitro and in vivo [16]. An important 
advantage of induced cell reprogramming is represented by the possibility of generating iPSC from patients 
showing sporadic or familial forms of the disease. These in vitro models are composed of cells that carry 
the patients’ genetic variants, some known and others not, that are key to the contribution of disease onset 
and progression. Moreover, given that iPSC can be further differentiated into neurons, this technology 
potentially provides, for the first time, an unlimited source of native phenotypes of cells specifically 
involved in the process related to neuronal death in neurodegeneration in vitro. 
One issue found in modeling PD with the use of iPSC is to correctly reproduce its late-onset 
characteristics, since aging is a crucial risk factor. Indeed, at first it was unclear whether disease-specific 
features of neurodegenerative disorders that usually progressively appear over several years were 
reproducible in vitro over a period of only a few days to a few months. As a consequence, iPSC were 
initially used to model neurodevelopmental phenotypes and a variety of monogenic early-onset  
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diseases [17–24]. However, studies using iPSC derived from patients with monogenic and sporadic forms 
of PD have illustrated these key features of PD pathophysiology, as a late-onset neurodegenerative 
disorder, after differentiating these iPSC into dopaminergic neurons. Moreover, several inducible factors 
that cause cell stress, such as mitochondrial toxins [25], growth factor deficiency, or even modulated aging 
with induced expression of progerin (a protein causing premature aging) [26], have also been used to 
accelerate and reproduce the phenotypes found during disease progression.  
 
Figure 1. Generation and use of iPSC modelling in PD. Somatic cells from a diseased 
patient are isolated and then reprogrammed to a pluripotent state (iPSCs). iPSCs can be 
maintained in culture or induced to differentiate along tissue- and cell-type specific 
pathways. Differentiated cells can be used to elucidate disease mechanism pathways, as 
well as for the development of novel therapies. 
In this review, the recent work on iPSC-based PD modeling for both sporadic and familial cases will be 
discussed, as well as how iPSC-based studies are helping in the advancement of novel drug discoveries. 
These studies give insight for the fundamental understanding of PD pathogenesis, which is critical for the 
development of new treatments. 
4. Modeling Sporadic and Familial PD Using iPSC 
Over the last few years, several studies have reported the generation of iPSC from patients suffering 
from sporadic and genetic forms of PD (Table 1). The first group generated PD-specific iPSC from a 
sporadic PD patient in 2008 [27]. Over the following year, the Jaenisch’s group was able to demonstrate 
that iPSC derived from PD patients were able to differentiate towards DAn, however, no characteristic 
signs of progressive neurodegeneration or disease-related phenotypes were observed in those cells [28]. 
The Jaenisch group generated gene-free iPSC lines from skin fibroblasts of five idiopathic PD patients. 
Using in vivo experiments, they showed that PD-specific iPSC-derived DAn were able to survive and 
engraft in the rodent striatum for at least 12 weeks. A small number of these cells co-expressed tyrosine 
hydroxylase (TH) and G-protein-gated inwardly rectifying K+ channel subunit (GIRK2), which are the 
hallmark characteristics of vmDAn. Remarkably, injection of these iPSC-derived DAn into the brains of  
6-OHDA-lesioned rats resulted in motor symptoms improvement [29]. 
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Table 1. Summary of the described PD iPSC modeling publications in this review. 





Cell Type Differentiation Findings 
SNCA  
Devine et al., 2011 [30] Triplication 1 NO 
Floor-plate DAn differentiation  
(21–30 days): 28%–37% TH+/TUJ1+ 
mRNA doubled expression of SNCA 
Byers et al., 2011 [31] Triplication 1 NO DAn differentiation (50 days): 6%–11% TH+
Double expression of SNCA,  
increased susceptibility to OS 
Chung et al., 2013 [32] A53T 2 YES 
Neuronal differentiation (56–84 days):  
DAn yield not specified. 
Increased nitrosative stress, and  
ER stress, reversed by adding NAB2. 
Ryan et al., 2013 [25] A53T 1 YES 
Kriks’s Floor-plate DAn differentiation:  
~80% A9 DAn of total neurons. 
Diminished spare respiration mitochondrial capacity;  
increased ROS/RNS and attenuation of MEF2/PGC1α 
neuroprotective pathway 
GBA1 




DAn diff. (30 days): 80% TUJ1+,  
10% TH+/TUJ1+ 
Formation of soluble α-syn oligomers, correlated  
with a decline of lysosomal proteolysis. 








Kriks’s Floor-plate DAn differentiation: 
15%–20% TH+/GIRK2+/FOXA2+/VMAT2+
There is also further purification  
of DAn by FACS 
Causal relation of GBA1 mutations with  
increased a-syn and LB inclusions, correlated with 
autophagic/lysosomal system impairment 
PARK2 




DAn differentiation (70 days): yield  
not specified 
Loss of Parkin function; decreased DA uptake and 
incorrectly folded DAT protein, with increased OS 
susceptibility. 
Transduction of WT PARK2 reversed OS sensitiveness. 
Imaizumi et al., 2012 [36] 





DAn differentiation (10 days): yield  
not specified 
Abnormal mitochondrial morphology  
and impaired mitochondrial homeostasis. 
PARK2 
PINK1 







Kriks’s Floor-plate DAn differentiation 
yield not specified 
Loss of dendrite lenght and decreased neuronal survival, 
as seen by decreased p-ATK values, when  
exposing mDA neurons to progerin. 
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Table 1. Cont. 





Cell Type Differentiation Findings 




Floor-plate DAn differentiation:  
11%–16% TH+/TUJ1+ 
Endogenous mutant PINK1 diminished Parkin 
recruitment to the mitochondrial membrane under the 
presence of valynomycin. WT PINK1  
rescued Parkin recruitment. 
(PINK1) Cooper et al., 2012 [38] Q456X 2 NO 
DAn differentiation (22 days): 35% TUJ1+; 
10% TH+ 
Increased vulnerability of neural cells  
to chemical stressors, with common defects  
to protect against OS. 
LRRK2 




Floor-plate DAn differentiation  
(30–35 days): 3.6%–5% TH+ 
α-syn accumulation, increased OS genes,  
and increased susceptibility to hydrogen peroxide. 







DAn diff (Lentiviral-mediated forced 
expression LMX1A in neural precursors)  
(75 days): 55% TH+/TUJ1+ (Majority 
TH+GIRK2+) 
Reduced neurite lenght and number.  
Accumulation of α-syn in LRRK2 DAn. 
Reduction of autophagic flux and  
accumulation of early autophagosomes. 
Orenstein et al., 2013 [41] G2019S 
4 LRRK2 
(G2019S) 
NO As described in [40] 
Blockage of the CMA degradation pathway due to 
accumulated α-syn with correlated  
increased expression of LAMP-2A. 
Reinhardt et al., 2013 [42] G2019S 2 YES 
Floor-plate DAn differentiation  
(30–35 days): 20% TH/TUJ1/DAPI 
Decreased neurite lenght levels.  
Increased ERK activation levels, and  
discover of novel genes dysregulated in LRRK2 DAn. 
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Many laboratories have now successfully recapitulated in vitro some of the characteristics of PD, using 
iPSC as a model compared to the aforementioned studies in which no signs of Parkinson’s disease were 
observed. However, given that PD is a progressive aging disease that affects several cellular mechanisms 
involving different cell types, each iPSC model highlights only some PD-associated characteristics. 
Nevertheless, each one of these models has helped to understand some of the fundamental underlying 
mechanisms as a proof-of-concept. In the last few years, iPSC-model reliability has rapidly improved and 
has paved the way for the discovery of new complex biomolecular interactions in the pathogenesis of PD. 
Thus, iPSC modeling has shown to be promising as a tool for drug-screening platforms in the future. 
Recently, iPSC-derived DA neurons carrying a triplication of SNCA, the coding gene for α-syn protein, 
have been generated [30,31]. These cells showed enhanced α-syn mRNA and protein levels [30] and 
increased cell death vulnerability when exposed to oxidative-stress inducers [31]. Using an iPSC model 
based on the rare missense A53T SNCA mutation, Chung et al. observed early pathogenic phenotype in 
patient-derived neurons, compared to isogenic gene-corrected controls. In particular, they observed a 
connection between nitrosative and ER stress in the context of α-syn toxicity. Interestingly, the levels of 
CHOP (CCAAT enhancer binding protein homologous protein), a component of ER stress-induced 
apoptosis, did not change, indicating that in this model cellular pathology was still at an early stage [32]. 
iPSC-derived DAn, carrying the A53T SNCA mutation, also showed α-syn aggregation, altered 
mitochondrial machinery, thus enhancing basal ROS/RNS production [25]. The increase of RNS 
production leads to S-nitrosylation of the pro-survival transcription factor MEF2 and its consequent 
inhibition, reducing the expression of the mitochondrial master regulator PGC1α and genes that are 
important for the development and survival of A9 DAn [43]. Interestingly, Ryan et al., postulated that the 
MEF2-PGC1α pathway contributes to the appearance of late-onset phenotypes in PD due to the complex 
interaction between environmental factors and gene expression. Indeed, when PD-associated pesticides 
were added below EPA-accepted levels, this was enough to exacerbate oxidative/nitrosative stress, 
inhibiting MEF2-PGC1α and inducing apoptosis, a late-onset phenotype [25]. 
Interestingly, α-syn is one of the main pathological readouts for many of the sporadic and familial PD 
cases that are not related with mutations in SNCA [44]. For example, the clinical link between the 
lysosomal storage disorder Gaucher disease (GD) and PD appears to be based on the fact that mutations in 
acid GBA1 gene, which causes GD, contributes to the pathogenesis of synucleinopathies [33,34]. GBA1 
encodes the lysosomal enzyme β-Glucocerebrocidase (GCase), which cleaves the β-glucosyl linkage of 
GlcCer. Functional loss of GCase activity in iPSC-derived neurons has been associated with compromised 
lysosomal protein degradation, which in turn induces α-syn accumulation, resulting in neurotoxicity 
through aggregation-dependent mechanisms [33]. In addition, iPSC-derived neurons carrying the 
heterozygous mutation in GBA1 also have shown increased levels of GlcCer, changes in the 
autophagic/lysosomal system and calcium homeostasis, which may cause a selective threat to DA neurons 
in PD [34]. 
Similarly to mutations in GBA1, mutations in PINK1 and PARK2 are also associated with early onset 
recessive forms of familial PD [45]. Both proteins, PINK1 and Parkin, are involved in the clearance of 
mitochondrial damage. Therefore their mutations cause a PD characterized by mitochondrial stress as main 
feature [46–48]. Under physiological conditions, Parkin, which is localized in the cytoplasm, is 
translocated to damaged mitochondria in a PINK-dependent manner triggering mitophagy [49]. This has 
been confirmed in iPSC-derived DA neurons carrying a mutation in PINK1. In these cells, Parkin 
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recruitment to mitochondria was impaired and only over-expression of WT PINK1 was able to rescue the 
function [37]. On the other hand, iPSC models for mutation in PARK2 revealed an increase of oxidative 
stress. Jiang and colleagues showed that iPSC from patients carrying mutations in PARK2 enhanced the 
transcription of monoamine oxidase, the spontaneous release of dopamine and significantly decreased 
dopamine uptake, increasing susceptibility to reactive oxygen species [35]. Although the incremented 
oxidative stress has been confirmed in a parallel study, in this study no difference in monoamine oxidase 
was observed [36]. On the contrary, the oxidative stress was accompanied by a compensation mechanism 
that involved the activation of the reducing Nrf2A pathway [36].  
Mutations in LRRK2 have been one of the most studied mutations in PD, not only because they are the 
most common cause of familial PD, but also because clinical symptoms of LRRK2-PD are similar to those 
of idiopathic PD [50]. The most common mutation is the G2019S, which results in  
hyper-activity of the LRRK2 kinase domain. Although penetrance of this gene has shown to be variable 
between individuals’ age, iPSC model of a G2019S LRRK2-PD has recapitulated characteristic features of 
PD, such as accumulation of α-syn, increase in genes responsible for oxidative stress and enhanced 
susceptibility to hydrogen peroxide, which is displayed through caspase-3 activation [39]. Furthermore, the 
expression of key oxidative stress-response genes and α-syn were found to be increased in neurons from 
LRRK2-iPSC, when compared to those differentiated from control iPSC or hESC.  
Our group has generated iPSC lines from seven patients with idiopathic PD and four patients carrying 
G2019S mutation in the LRRK2 gene [40]. We observed morphological alterations in PD-derived iPSC 
vmDAn (fewer and shorter neurites) as well as an increase in the number of apoptotic neurons over a  
long-time culture (2.5 months). Moreover, we found an accumulation of α-syn in LRRK2-iPSC derived 
DAn after a 30 days culture. 
Sporadic forms of PD are not as well defined, given that they may be caused by several genetic variants, 
as well as a strong environmental effect. However, our study revealed that DAn, which were derived from 
idiopathic PD patients, also showed an increased susceptibility to degeneration in vitro after long-term 
culture [40].  
Importantly, the appearance of the neurodegenerative phenotypes in differentiated DAn from either 
idiopathic or LRRK2-associated PD was shown to be the consequence, at least in part, of impaired 
autophagy. Blockade of autophagy by lysosomal inhibition showed a specific reduction in autophagic flux 
by LC3-II immunoblotting, suggesting that the clearance of autophagosomes was compromised [40]. 
Proteins may also enter the autophagic process directly at the lysosome level, via chaperone-mediated 
autophagy (CMA). Increased co-localization of α-syn with LAMP2A puncta in iPSC-derived LRRK2 DAn, 
revealed a compromised degradation of α-syn by CMA [41]. Although both wild-type and mutant LRRK2 
inhibit CMA, G2019S LRRK2 protein was more resistant to the CMA-mediated degradation, resulting in 
α-syn accumulation [41]. Furthermore, the same phenotype was induced by over-expression of wild-type 
or G2019S LRRK2 in control iPSC-derived cultures [40] and rescued by LRRK2 inhibition [42]. Indeed, 
iPSC-derived DAn cultures from isogenic G2019S LRRK2 lines (mutation being the sole experimental 
variable) exhibited an increased mutant-specific apoptosis and decreased neurite outgrowth, as well as 
alterations in the expression of several pERK (phosphorylated ERK) controlled genes, all of which could 
be rescued by the inhibition of LRRK2 [42]. Moreover, the genetic correction of LRRK2 mutation resulted 
in the phenotypic rescue of differentiated neurons with improved neurite length to levels comparable to 
those of controls.  
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5. Patient-Derived Stem Cells Could Improve Drug Research for PD 
An important goal of humanized stem cell-based PD model systems is the screening of potential new 
drugs that could affect the neurodegenerative process at several levels during its development in 
specifically affected human cells. Moreover, the availability of such patient-specific stem cell-based model 
systems could help identifying new pharmacological strategies for the design of personalized therapies. 
Recently, iPSC-derived forebrain neurons have been used as a platform to screen disease-modifying drugs, 
highlighting the possibilities of iPSC technology as an in vitro cell-based assay system for AD  
research [51]. A recent study has also taken a significant leap towards personalized medicine for PD 
patients, by investigating signs of the disease in patient-specific iPSC-derived neurons and testing how the 
cells respond to drug treatments [38]. The study showed that neurons derived from PD patients carrying 
mutations in the PINK1 or LRRK2 genes display common signs of distress and vulnerability such as 
abnormalities in mitochondria and increased vulnerability to oxidative stress. However, they found that 
oxygen consumption rates were lower in cells with mutations in LRRK2 and higher in cells with the 
mutations in PINK1. Notably, they were able to rescue the phenotype caused by toxins to which the cells 
were exposed to with various drug treatments, including the antioxidant coenzyme Q10 and rapamycin. 
Most importantly, the response of iPSC-derived neurons was different depending on the type of familial 
PD, since drugs that prevented damage to neurons with mutations in LRRK2, did not protect neurons with 
mutations in PINK1 [38].  
In addition, Ryan and colleagues performed a high-throughput screening (HTS) to identify molecules 
that are capable of protecting DAn from the toxic effect of PD-associated pesticides. They observed that 
the MEF2-PGC1α pathway contributes to the late-onset PD phenotypes due to the interaction between 
environmental factors and gene expression [25]. They performed HTS for small molecules capable of 
targeting the MEF2-PGC1α pathway and they identify isoxazole as new potential therapeutic drug. 
Isoxazole, not only drove the expression of both MEF2 and PGC1α, but also protected A53T DAn from 
pesticide-induced apoptosis [25]. 
Chung and colleagues investigated yeast and iPSC PD models in parallel to discover and reverse 
phenotypic responses to α-syn. In conjunction to what was previously reported, they showed a connection 
between α-syn toxicity, accumulation of NO and ER stress [32]. With these results, they took a step further 
by screening for possible α-syn toxicity suppressors in their iPSC model, to compare with their previous 
yeast screenings [52–54]. In particular they showed that the ubiquitin ligase Nedd4 and its chemical 
activator NAB2 [53] are able to rescue the α-syn toxicity in patient-derived neurons [32], opening a door to 
a new potential drug treatment.  
These results encourage the use of iPSC technology as a tool to discover potential therapeutic drugs. 
However, concluding for what recent studies have unveiled up until now focusing only on genetic forms of 
PD, it remains to be determined whether this advanced technology can be used also in sporadic patients 
with uncertain genetic cause of the disease.   
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6. Limitations of Using iPSC in Disease Modeling: From Overall Neurodegeneration to the 
Detailed Mechanisms Involved 
6.1. Reprogramming and Epigenetic Signatures 
Reprogramming increases cell variability due to the introduction of mutations in the genomic DNA [55] 
and the insertion of exogenous reprogramming genes. Moreover reprogrammed cells maintain a residual 
DNA methylation signature characteristic of the somatic tissue of origin [56–59] affecting also gene 
expression [60]. These issues can affect the predisposition of a given line to differentiate into particular cell 
type independently of the patient’s genotype, and will abrogate the possibility of using these lines for cell 
therapy treatment in the future. To decrease the impact of these technical limitations, more than one clone 
for each iPSC line is usually analyzed. However, the use of integrating methods, such as lenti- and  
retro-virus infection for gene transduction, not only increases cell variability, but also maintains residual 
expression of exogenous reprogramming genes that is only partially lost through cell passaging. The 
residual expression of reprogramming genes can, not only create problems during cell differentiation, but 
overall iPSC do not need a constant over expression of reprogramming genes. Indeed, the reprogramming 
process by which a somatic cell acquires pluripotent potential is not a genetic transformation, but an 
epigenomic one [61], therefore only a transient expression of reprogramming genes needs to be activated. 
Alternative methods to the retro- or lenti-viral infection, have been recently adopted. These include the use 
of non-integrating viral vectors such as Sendai virus [62], episomal vectors [63], protein transduction [64], 
or transfection of modified mRNA transcripts [65]. These methods of reprogramming are relevant in the 
context of any future clinical applications of iPSCs in the field of transplantable replacement cell therapies. 
As aforementioned, one of the major concerns in iPSC modeling through the reprogramming of somatic 
cells into iPSCs has been that of resetting the identity of these cells back to an embryonic stage, therefore 
having to consider the generated iPSC-derived neurons as fetal neurons. Given the slow progression of 
neurodegenerative diseases, the idea of modeling this type of disease in a dish has been highly doubted. 
However, despite the typical late-onset of PD, the key cellular and molecular pathological mechanisms 
may have started before the onset of the disease. Therefore, α-syn accumulation, autophagic clearance and 
mitochondrial dysfunctions, among other pathological mechanisms afforested, could have been active in 
the early stages of the disease. The cumulative effect of these abnormalities along with the effect of 
environmental influence, have been shown to progressively encourage neurodegeneration [25]. In addition 
the use of cell stressors and inducible aging [26] also have shown the possibility of accelerating the 
appearance of diseased phenotypes in a dish. 
6.2. Reliable Control Lines and Gene-Editing 
Comparative studies require an appropriate control that accounts for differences between lines due only 
to the genotypic background that exists between individuals. This is especially crucial in diseases whose 
causative mutations do not have a high penetrance. For example, when complex diseases, such as PD, are 
modeled with patient- and healthy donor-derived iPSC, the patient iPSC tend to show subtle phenotypes 
that can be masked by genetic background effects [66]. For this reason, it is imperative to remove the 
excess genetic variation between iPSC clones and controls, to ensure a more reliable comparative analysis. 
Given that to obtain iPSC from unaffected siblings or parental controls is not often possible, a solution is to 
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generate isogenic controls directly from the patient iPSCs. In the last years, several research groups have 
used this approach to correct known mutations [25,26,32,34,42,67], or even utilizing the introduction of the 
same mutation in control iPSC lines to see the effect of just the mutation itself [42,67]. For this reason, 
isogenic controls have claimed to be crucial when it comes to assess the impact of any mutation on specific 
cellular processes. Therefore, editing technologies based on Zinc Fingers Nucleases, TALENs or  
CRISPR [68], have become indispensable tools in developing comparative studies in iPSC models, 
allowing for the reduction of iPSC cohorts. 
6.3. Cell Differentiation and Sorting 
The efficacy of Parkinson’s disease iPSC models depends highly on their ability to correctly 
differentiate neurons into the specific cell type that is affected by the disease (in this case A9 dopaminergic 
neuronal subtype). Indeed this is critical in order to recapitulate disease features in vitro and observe 
comparative differences between diseased and healthy control lines. Neuronal differentiation of iPSC into 
DA neurons is not only subjected to high variability of efficiency, depending on the techniques used in a 
laboratory, but also on the specific ability of each iPSC line. For example, by comparing the studies 
reported in this review, the percentage of DA neurons compared to the total number of cells varies 
depending on each cell line, differentiation method and even laboratory group (Table 1). Throughout the 
field, groups encountered problems in yielding a high percentage of DA neurons within the differentiated 
population. Therefore, although a number of results are based on the disease phenotype through the 
identification of TH positive cells by immunocytochemistry, protein immunoblots in which all cell 
populations are considered skews the data. More specifically, the levels of affected protein in the few TH 
positive cells may be diluted and missed when mixed with the whole population of differentiate cells when 
analyzed. Interpretation of these results have been, thus, controversial, especially in the cases in which PD 
iPSC-derived models have low yield in DA differentiation, which probably cannot go beyond the gross 
neurodegeneration mechanisms that they have observed. Thus, delving deep inside the biomolecular 
pathways affected in PD will require a more fine-tuned differentiation protocol that allows the enrichment 
of the cell type of interest. To achieve this, a novel floor-plate-based strategy described by Kriks and 
colleagues has become the gold standard in the generation of human A9 vmDA neurons for both 
transplantation and research purposes [69]. The protocol is based on the concurrent inhibition of two 
parallel SMAD/TGF-β (transforming growth factor-β) superfamily-signaling pathways, which during CNS 
development induce no-neuronal fates such as endoderm or mesoderm. This inhibition directs the cell 
culture to a predetermined neural progenitor fate with an efficiency of at least 80% of PAX6+ neural cells 
among total cells [70]. Differentiation of these neuronal stem cells into mature vmDAn is then instructed 
through the molecular guidance of Sonic Hedgehog (SHH), FGF8 and more importantly Wnt signaling 
pathway induction, which enhances expression of the transcription factors FOXA2 and LMX1A [71,72]. 
The final step of neuronal maturation is achieved through the use of a cocktail of neurotrophic factors, 
including BDNF, GDNF, TGFβ3, dbcAMP, and ascorbic acid (Figure 2). Interestingly, the most recent 
papers reviewed here have started to implement the A9 vmDAn enrichment protocol [25,26,34] with the 
addition of isogenic-corrected controls [25,34]. Moreover, Schöndorf and colleagues improved the Kriks 
differentiation protocol thanks to the use of a cell sorting method (Fluorescence-activated cell sorting), 
which allowed for a 6.1-fold enrichment of the neuronal population. This step of sorting was necessary to 
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assess reliable biomolecular changes that could not have been assessed with an unsorted heterogenic 
population [34]. 
 
Figure 2. Schematic summary of the novel floor-plate A9 vmDAn differentiation protocol 
by Kriks [69]. The first stage illustrates floor-plate induction [70], with the appropriate 
modification in order to reach a more specialized A9 midbrain DA neuronal identity. 
Exposure to LDN (LDN193189) and SB (SB431542) triggers the Dual-SMAD inhibition. 
Purmorphamine (Pur), which activates Sonic Hedgehog (SHH) signaling, together with 
SHH and FGF8 is not sufficient to trigger a selective enrichment of midbrain DA 
precursors. However, SHH/Pur/FGF8 in combination with exposure to CHIR99021 (a 
potent GSK3β inhibitor known to strongly activate WNT signaling) allows for a  
complete enrichment of DA precursors with A9 midbrain identity, by inducing the 
expression of FOXA2 and LMX1A. Neural differentiation and maturation is achieved 
through the use of a cocktail of neurotrophic factors BAGCT (BDNF + ascorbic acid + 
GDNF + dbcAMP + TGFβ3). 
On the other hand, to unveil the mechanisms behind pathophysiological processes such as 
neuroinflammation, the investigation of all cells responsible for the maintenance of CNS homeostasis, such 
as astrocytes and microglia, is crucial. Nevertheless, the study of a more isolated system may allow 
investigators to detect early events of a disease that would otherwise be missed.  
7. Conclusions and Challenges 
PD is a progressive neurodegenerative disease resulting in the gradual loss of vmDA neurons, as well as 
cytoplasmic inclusions called Lewy Bodies. The exact mechanisms leading to vmDA neuronal death in PD 
are still unclear, although pathogenic protein aggregation of α-synuclein, mitochondrial dysfunction, 
oxidative and nitrosative stress, or altered autophagy have been proposed as mechanisms that contribute to 
this devastating neurodegenerative process. The generation of reliable iPSC-based models for late-onset 
neurodegenerative disorders, in which the etiology is yet to be uncovered, has proven to be difficult to 
overcome. However, recent advances in the field have demonstrated the feasibility of developing 
experimental models of PD based on iPSC from patients of both genetic and idiopathic forms of PD that 
recapitulate the key features of the disease. The successful generation of these genetic and idiopathic PD 
models has opened the door bringing to light some of the crucial pathogenic mechanisms responsible for 
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the initiation and progression of PD, as well as aid in the development of novel drugs that may prevent or 
rescue neurodegeneration in PD. Recent findings in the field have moved far beyond the proof-of-principle 
stage, and have started to optimize and standardize these models for the discovery of new aspects of 
disease biology and new targets for therapeutic intervention. The use of isogenic-corrected controls, more 
reliable differentiation protocols [25,26,34] and efficient cell-sorting methods [34], have strongly validated 
the reliability of iPSC models in the context of complex diseases such as PD. Within the field of 
neuroscience, the opportunity and challenge to combine patient-derived disease-specific stem cells with 
drug screening technologies with the aim of finding new therapies is now a possibility. In addition, the 
combination of establishing optimal neuronal differentiation protocols of iPSC using genetic reporters, 
together with software analysis algorithms, allows for the possibility of automatically tracking each cell 
over time and to assess any feature of interest, thus providing this system with a powerful tool in drug 
discovery in the near future. 
Moreover, by studying symptomatic and asymptomatic mutation carriers, iPSC technology could also 
provide a unique opportunity for identifying putative gene-linked PD biomarkers in pre-symptomatic 
individuals, opening a new novel window for the early diagnosis and individualized treatment in the 
preclinical phase of the disease. 
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